Trinh Hon, Stevens Nathan, Adams Gerard, Chee Raphael, Ha Tuan, Knesl Marcel, Mitchell Jack, Nagpal Sakshi, Sia Edward, Xing Daniel
NSW Health; Illawarra Shoalhaven Cancer and Haematology Network, Nowra, Australia.
University of Wollongong, Wollongong, Australia.
J Med Imaging Radiat Oncol. 2025 Sep;69(6):687-695. doi: 10.1111/1754-9485.13883. Epub 2025 Aug 7.
This paper reports the key findings of the Faculty of Radiation Oncology 2022 workforce census. This is the first census since the COVID-19 pandemic and questions have been updated to assess the impact on RANZCR trainees and fellows. This report focuses on the analysis of respondents from Australia, New Zealand and overseas members, with a separate paper to follow focusing exclusively on New Zealand respondents.
The census was conducted in mid-late 2022 with many questions repeated from previous censuses. New questions were asked about theranostics, working remotely, hypofractionation and the impact of COVID-19 on work practices.
The census was sent to 591 radiation oncologists with an overall response rate of 52%. Almost half of respondents (n = 94/210; 45%) indicated that COVID-19 had no impact on the uptake of hypofractionation. Hypofractionation was most used by respondents in breast and prostate treatment (n = 134/200; 67% and n = 112/194; 58% respectively). Five respondents (n = 5/270; 2%) currently practise in theranostics, with the majority treating thyroid cancers within the public sector. Just under half (n = 81/167; 49%) of invited trainees responded. The majority felt that COVID-19 had a negative impact on their training. There has been a decrease in the number of new fellows seeking to complete further fellowships. Employment remains at very high levels for new fellows ( > 98%).
The impact of COVID-19 on local practices and workloads was not as significant as seen overseas. There continues to be an increasing trend of radiation oncologists working in the private sector. The lack of indigenous representation within our profession continues to be an area that needs further attention.
本文报告了放射肿瘤学系2022年劳动力普查的主要结果。这是自新冠疫情以来的首次普查，相关问题已更新，以评估对皇家澳大利亚和新西兰放射肿瘤学家学会（RANZCR）学员和研究员的影响。本报告重点分析了来自澳大利亚、新西兰和海外成员的受访者情况，后续将有一篇单独的论文专门关注新西兰受访者。
普查于2022年年中至年末进行，许多问题与之前的普查重复。新增了关于治疗诊断学、远程工作、大分割放疗以及新冠疫情对工作实践影响的问题。
普查问卷共发送给591名放射肿瘤学家，总体回复率为52%。近一半的受访者（n = 94/210；45%）表示新冠疫情对大分割放疗的采用没有影响。大分割放疗在乳腺癌和前列腺癌治疗中的应用最为广泛（分别为n = 134/200；67%和n = 112/194；58%）。五名受访者（n = 5/270；2%）目前从事治疗诊断学工作，其中大多数在公共部门治疗甲状腺癌。受邀学员中近一半（n = 81/167；49%）回复了问卷。大多数人认为新冠疫情对他们的培训有负面影响。寻求完成进一步进修的新研究员人数有所减少。新研究员的就业率仍然很高（> 98%）。
新冠疫情对当地实践和工作量的影响不如在海外那么显著。在私营部门工作的放射肿瘤学家数量持续呈上升趋势。我们这个行业中缺乏原住民代表的情况仍然是一个需要进一步关注的领域。
